et al. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc. 1993; 68 :860–866.O’Brien T, Dinneen SF, O’Brien PC, et al. Hyperlipidemia in patients with primary and secondary hypothyroidism . Mayo Clin Proc 1993; 68 : 860–6...
Type IIa hyperlipidemia was the most common lipid abnormality in patients with primary hypothyroidism, whereas type IIb was the most common in those with secondary hypothyroidism. Total/high-density lipoprotein cholesterol and low-density lipoprotein/high-density lipoprotein cholesterol ratios were increased...
Clinical trials have established that secondary prevention of hyperlipidemia in patients after coronary artery bypass graft (CABG) surgery prevents progression of atherosclerosis. A multidisciplinary team promotes secondary prevention by prescribing antihyperlipidemic agents, screening for risk factors, and providi...
We excluded volunteers with uncontrolled hypertension, secondary hyperlipidemia, or type 1 or type 2 diabetes mellitus that was either managed with insulin or associated with a glycohemoglobin level of at least 10% (20% above the upper limit of normal). Additionally, volunteers were excluded if, ...
Taken together, the efficacy of folic acid therapy in stroke prevention should be evaluated and interpreted in the context of primary vs secondary prevention and individual and combined effects of baseline folate levels and MTHFR gene C677T polymorphism. The China Stroke Primary Prevention Trial (CS...
Hyperlipidemia is a major modifiable risk factor for CV disease, and ... Dean G. Karalis - 《Advances in Therapy》 被引量: 7发表: 2017年 Appropriate primary prevention of cardiovascular disease: does this mean more or less statin use? Treatment with HMG-CoA reductase inhibitors, commonly ...
47, 48 We created four clusters of related conditions: “metabolic disorders” (hypertension, hyperlipidemia, diabetes, and coronary artery disease), “psychiatric disorders” (mood disorders and anxiety disorders), “respiratory disorders” (asthma and other upper respiratory disorders), and “...
We hypothesize that PATHWEIGH will lead to greater weight loss at 6 months (primary) and greater weight loss maintenance at 12 and 18 months (secondary) compared to SOC [Hypothesis I]. Key patient, clinician, and clinic characteristics will mediate and moderate patient weight loss and weigh...
The objective of this study was to compare the lifetime cost-effectiveness of HMG-CoA reductase inhibitors and fibrates for the treatment of hyperlipidemia. Estimates of lipid modification achieved due to drug therapy were based on published head-to-head comparisons of specific HMG-CoA reductase inhi...
31 We did not systematically collect information on lipid-modifying therapy, but we did so for hyperlipidemia. Among women who remained normolipemic throughout the trial and who were unlikely to have taken lipid-modifying drugs, we observed no significant effect of vitamin E on major ...